Original language | English (US) |
---|---|
Pages (from-to) | 1863-1865 |
Number of pages | 3 |
Journal | Circulation |
Volume | 136 |
Issue number | 19 |
DOIs | |
State | Published - Jun 23 2017 |
Keywords
- Cardiovascular diseases
- Guideline
- Hydroxymethylglutaryl-CoA reductase inhibitors
- Lipoproteins
- Primary prevention
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology (medical)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Circulation, Vol. 136, No. 19, 23.06.2017, p. 1863-1865.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - High-quality statin trials support the 2013 American College of Cardiology/American Heart Association cholesterol guidelines after the HOPE-3 trial (heart outcomes prevention evaluation-3)
T2 - MESA (The multiethnic study of atherosclerosis)
AU - Mortensen, Martin Bødtker
AU - Budoff, Matthew
AU - Li, Dong
AU - Nasir, Khurram
AU - Blaha, Michael J.
AU - Sandfort, Veit
AU - Rodriguez, Carlos Jose
AU - Ouyang, Pamela
AU - Falk, Erling
N1 - Funding Information: This research was supported by contracts HHS-N268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Institutes of Health's National Heart, Lung, and Blood Institute and by grants UL1-TR-000040 and UL1-TR-001079 from the National Center for Research Resources. Funding Information: From Department of Cardiology, Aarhus University Hospital, Denmark (M.B.M., E.F.); Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA (M.B., D.L.); Center for Healthcare Advancement & Outcomes Baptisk Health South Florida, Miami (K.N.); Department of Epidemiology, Robert Stempel College of Public Health and Department of Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami (K.N.); The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD (M.J.B.); Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD (V.S.); Division of Public Health Sciences, Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC (C.J.R.); and John Hopkins University School of Medicine, Baltimore, MD (P.O.). Funding Information: This research was supported by contracts HHS-N268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Institutes of Health’s National Heart, Lung, and Blood Institute and by grants UL1-TR-000040 and UL1-TR-001079 from the National Center for Research Resources.
PY - 2017/6/23
Y1 - 2017/6/23
KW - Cardiovascular diseases
KW - Guideline
KW - Hydroxymethylglutaryl-CoA reductase inhibitors
KW - Lipoproteins
KW - Primary prevention
UR - http://www.scopus.com/inward/record.url?scp=85021299585&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021299585&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.117.029381
DO - 10.1161/CIRCULATIONAHA.117.029381
M3 - Letter
C2 - 28634218
AN - SCOPUS:85021299585
SN - 0009-7322
VL - 136
SP - 1863
EP - 1865
JO - Circulation
JF - Circulation
IS - 19
ER -